title: Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease.
authors.forename: P
authors.initials: P
authors.lastname: Rosenstiel
authors.forename: J
authors.initials: J
authors.lastname: Agnholt
authors.forename: J
authors.initials: J
authors.lastname: Kelsen
authors.forename: V
authors.initials: V
authors.lastname: Medici
authors.forename: G H
authors.initials: GH
authors.lastname: Waetzig
authors.forename: D
authors.initials: D
authors.lastname: Seegert
authors.forename: S
authors.initials: S
authors.lastname: Schreiber
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D003424:Crohn Disease / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D018928:Immunity, Mucosal / Q000187:drug effects; D007074:Immunoglobulin G / Q000494:pharmacology*; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor; D015398:Signal Transduction / Q000187:drug effects; D016176:T-Lymphocyte Subsets / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068800:Etanercept